A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） - Trial NCT04615468
Access comprehensive clinical trial information for NCT04615468 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 78 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 2
Dec 01, 2020
Oct 31, 2022
Primary Outcome
Overall response rate (ORR) by Independent Review Committee
Summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with
 relapse/refactory peripheral T-cell lymphoma who have received at least 1 lines of
 therapeutic schedules. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04615468
Non-Device Trial